In this episode:
In this podcast first recorded at the 2020 IO360° Summit, Dr Aiman Shalabi, GSK, moderated a cell and gene therapy debate on intrinsic editing vs systemic combination
Participants included:
- Mark O’Hara, MD, University of Pennsylvania
- Saul Priceman, PhD, City of Hope
To learn more about the Immuno-Oncology 360° Conference, please visit IO360Summit.com.
Related Podcasts
View All
The History of Tumor Vaccines, and Why the Newest RNA Vaccines May Work Where Others Could Not
Combining AI and Empirical Science to Advance Cancer Immunotherapies
Getting Under the Hood of AI to Find Its Value for Immuno-Oncology
